SCHEDULE: OrbiMed Amends X4 Pharma Stake to 1.7%
Beneficial Ownership Disclosure
OrbiMed Advisors LLC has filed an Amendment No. 5 to its Schedule 13G, disclosing a 1.7% beneficial ownership in X4 Pharmaceuticals, Inc. common stock.
Summary
- OrbiMed Advisors LLC reported beneficial ownership of 134,947 warrants to purchase common stock of X4 Pharmaceuticals, Inc.
- This represents 1.7% of the class of common stock.
- OrbiMed Advisors LLC holds shared voting and dispositive power over these 134,947 warrants.
- The filing is an Amendment No. 5 to a Schedule 13G.
- OrbiMed Advisors LLC is classified as an Investment Adviser (IA).
Sentiment
Score: 5
Explanation: The filing is a routine ownership disclosure (Schedule 13G Amendment) and does not contain information that would inherently indicate positive or negative sentiment. It is a factual report of beneficial ownership.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- The filing indicates OrbiMed Advisors LLC holds 1.7% of X4 Pharmaceuticals, Inc. common stock, which provides transparency to shareholders regarding institutional ownership.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement |
| 08/14/2025 | Signature date of the filing |
Keywords
X4 Pharmaceuticals, OrbiMed Advisors, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.